Valuation: Amgen Inc.

Market Cap 248B 384,603B 225B 208B 187B 354B 23,143B 367B 2,503B 990B 12,488B 929B 910B 39,456B P/E 2026 *
23.6x
P/E 2027 * 22.5x
Enterprise Value 287B 445,719B 261B 241B 217B 410B 26,820B 426B 2,901B 1,147B 14,473B 1,077B 1,054B 45,726B EV / Sales 2026 *
7.27x
EV / Sales 2027 * 6.82x
Free-Float
99.76%
Yield 2026 *
2.2%
Yield 2027 * 2.33%
1 day-0.15%
1 week+0.78%
1 month+10.68%
3 months+18.46%
6 months+59.75%
Current year+54.77%
1 week 25,640
Extreme 25640.00000000
26,460
1 month 22,980
Extreme 22980
27,800
Current year 15,920
Extreme 15920
27,800
1 year 15,700
Extreme 15700
27,800
3 years 7,000
Extreme 7000
27,800
5 years 1,396.67
Extreme 1396.666666
27,800
10 years 273.67
Extreme 273.666666
27,800
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+0.78% - - 248B
-1.13%-1.17%+38.55%+139.23% 1,261B
-1.36%-0.74%+39.64%+86.06% 671B
-0.59%-0.36%+25.14%+111.73% 518B
+0.01%+1.17%+32.57%+71.45% 387B
-0.75%-3.16%+54.39%+40.90% 353B
-0.41%+0.02%+30.16%+57.52% 300B
-0.75%-1.27%+1.14%+35.76% 283B
-0.95%-1.57%+34.01%+72.55% 248B
+1.60%-0.36%+37.21%+125.66% 211B
Average -0.36%-0.37%+32.53%+82.32% 470B
Weighted average by Cap. -0.32%-0.55%+34.43%+95.74%

Financials

2026 *2027 *
Net sales 39.47B 61,280B 35.83B 33.1B 29.86B 56.37B 3,687B 58.53B 399B 158B 1,990B 148B 145B 6,287B 41.26B 64,067B 37.46B 34.6B 31.22B 58.93B 3,855B 61.19B 417B 165B 2,080B 155B 152B 6,573B
Net income 10.52B 16,338B 9.55B 8.82B 7.96B 15.03B 983B 15.6B 106B 42.05B 530B 39.48B 38.65B 1,676B 10.78B 16,743B 9.79B 9.04B 8.16B 15.4B 1,007B 15.99B 109B 43.1B 544B 40.46B 39.61B 1,718B
Net Debt 39.36B 61,115B 35.73B 33.01B 29.78B 56.22B 3,678B 58.37B 398B 157B 1,984B 148B 145B 6,270B 33.8B 52,482B 30.68B 28.34B 25.57B 48.27B 3,158B 50.12B 342B 135B 1,704B 127B 124B 5,384B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
17/11/26 ARS 25,800.00 -0.15% 550
16/11/26 ARS 25,840.00 -0.46% 708
13/11/26 ARS 25,960.00 -0.31% 862
12/11/26 ARS 26,040.00 +0.31% 569
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
457.93USD
Average target price
432.84USD
Spread / Average Target
-5.48%